Dr. Glenn Haifer and Ampersand Capital Partners acquire Australian biopharmaceutical CDMO Luina Bio and rebrand it as AcuraBio.
Adelaide, Australia, August 31, 2022 - (JCN Newswire) - AcuraBio, one of Australia's leading biopharmaceutical CDMOs (formerly Luina Bio), has been acquired by Dr. Glenn Haifer, a biotechnology investor, and Ampersand Capital Partners, a globally operating healthcare-focused private equity fund.
With over 20 years of experience, AcuraBio is a global company that provides innovative therapeutics to clients in the biotechnology, pharmaceutical, and animal health industries, offering recombinant proteins, vaccines, and complex biologic products to customers at the forefront of new therapies.
This rebranding symbolizes a new growth phase of innovation at AcuraBio. As part of this transaction, Dr. Haifer and Ampersand will make significant investments in AcuraBio, focusing on organizational expansion to provide better services to customers. AcuraBio plans to enhance its production facilities to drive further growth and is actively considering the expansion of new services and technological capabilities.





